HDAC9 and lung adenocarcinoma: Also, Zheng H. et al. [82] have found that class I HDAC inhibitor romidepsin induced a strong T cell-dependent antitumor response and enhanced the therapeutic effect of PD-1 inhibitors in lung adenocarcinoma.